DNA vaccine reduces toxic proteins linked to Alzheimer's ...
A study has found that a DNA vaccine tested in mice reduces accumulation of both toxic proteins associated with Alzheimer's disease (beta-amyloid and tau).
www.alzheimers.org.ukHere’s the latest on dementia vaccines, based on recent public reporting up to 2025–2026.
-
What’s new: There has been continued research into vaccines and immune therapies aimed at reducing key pathological proteins like beta-amyloid and tau in Alzheimer’s disease. Early-stage studies (often in animals) show promise in reducing these proteins and delaying disease progression, but none has yet completed large-scale human trials with proven clinical benefit. This remains an active research area with cautious optimism rather than established clinical use.[2][3][8]
-
Key developments by year:
- 2018–2019: Several teams reported that DNA- or peptide-based vaccines could lower toxic brain proteins in animal models, fueling plans for human trials. These studies highlighted the potential for vaccines to slow onset or progression if translated to people.[1][3]
- 2020–2021: Research groups and academic centers continued to publish preclinical success and outlined pathways to human testing, often focusing on multi-target approaches addressing both beta-amyloid and tau.[6]
- 2024–2025: Public statements and reviews summarized early findings, noting that some vaccine strategies and adjuvant systems showed reduced pathological proteins in models, with ongoing discussions about safety, immune response, and trial design in humans.[4][8]
-
Practical outlook for patients and caregivers in Marseille/Provence: At present, dementia vaccines are not yet approved or available as standard preventive or disease-modifying therapies. Participation in clinical trials may be available through academic medical centers or research networks; discuss with your neurologist or local dementia research centers about ongoing trials or upcoming opportunities.[5][8]
-
What to watch next: Large, well-designed human trials assessing safety, efficacy, and long-term outcomes are required before any vaccine becomes standard care. Look for announcements from major research consortia or biotech/pharma companies about phase 2/3 trials and regulatory submissions.[9][4]
Illustration: a simplified view of the vaccine concept in dementia research
- Vaccine design aims to teach the immune system to target pathological brain proteins (amyloid beta and tau) to slow or prevent neurodegeneration. Real-world success hinges on balancing immune activation with safety in humans.
Would you like me to pull the most recent press releases from specific institutions or identify ongoing trials you could discuss with a local clinician in Marseille? I can also summarize any particular study in more detail.[8][9]